Market Analysis and Insights: Global Follicular Lymphoma Treatment Market
The research report studies the Follicular Lymphoma Treatment market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Follicular Lymphoma Treatment market size is projected to reach US$ 2691 million by 2027, from US$ 1681.7 million in 2020, at a CAGR of 6.5% during 2021-2027.
Global Follicular Lymphoma Treatment Scope and Segment
The global Follicular Lymphoma Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Follicular Lymphoma Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Chemotherapy
Radiotherapy
Monoclonal Antibodies
Stem Cell Transplantation
by Application, this report covers the following segments
Hospital
Clinic
Others
Global Follicular Lymphoma Treatment market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Follicular Lymphoma Treatment key players in this market include:
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Cellular Biomedicine Group, Inc.
Coherus BioSciences, Inc.
CTI BioPharma Corp.
Curis, Inc.
Dynavax Technologies Corporation
Eisai
EpiZyme, Inc.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
Immune Design Corp.
ImmunoGen, Inc.
The research report studies the Follicular Lymphoma Treatment market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Follicular Lymphoma Treatment market size is projected to reach US$ 2691 million by 2027, from US$ 1681.7 million in 2020, at a CAGR of 6.5% during 2021-2027.
Global Follicular Lymphoma Treatment Scope and Segment
The global Follicular Lymphoma Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Follicular Lymphoma Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Chemotherapy
Radiotherapy
Monoclonal Antibodies
Stem Cell Transplantation
by Application, this report covers the following segments
Hospital
Clinic
Others
Global Follicular Lymphoma Treatment market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Follicular Lymphoma Treatment key players in this market include:
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Cellular Biomedicine Group, Inc.
Coherus BioSciences, Inc.
CTI BioPharma Corp.
Curis, Inc.
Dynavax Technologies Corporation
Eisai
EpiZyme, Inc.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
Immune Design Corp.
ImmunoGen, Inc.
1 Market Overview of Follicular Lymphoma Treatment
1.1 Follicular Lymphoma Treatment Market Overview
1.1.1 Follicular Lymphoma Treatment Product Scope
1.1.2 Follicular Lymphoma Treatment Market Status and Outlook
1.2 Global Follicular Lymphoma Treatment Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Follicular Lymphoma Treatment Market Size by Region (2016-2027)
1.4 Global Follicular Lymphoma Treatment Historic Market Size by Region (2016-2021)
1.5 Global Follicular Lymphoma Treatment Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Follicular Lymphoma Treatment Market Size (2016-2027)
1.6.1 North America Follicular Lymphoma Treatment Market Size (2016-2027)
1.6.2 Europe Follicular Lymphoma Treatment Market Size (2016-2027)
1.6.3 Asia-Pacific Follicular Lymphoma Treatment Market Size (2016-2027)
1.6.4 Latin America Follicular Lymphoma Treatment Market Size (2016-2027)
1.6.5 Middle East & Africa Follicular Lymphoma Treatment Market Size (2016-2027)
2 Follicular Lymphoma Treatment Market Overview by Type
2.1 Global Follicular Lymphoma Treatment Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Follicular Lymphoma Treatment Historic Market Size by Type (2016-2021)
2.3 Global Follicular Lymphoma Treatment Forecasted Market Size by Type (2022-2027)
2.4 Chemotherapy
2.5 Radiotherapy
2.6 Monoclonal Antibodies
2.7 Stem Cell Transplantation
3 Follicular Lymphoma Treatment Market Overview by Application
3.1 Global Follicular Lymphoma Treatment Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Follicular Lymphoma Treatment Historic Market Size by Application (2016-2021)
3.3 Global Follicular Lymphoma Treatment Forecasted Market Size by Application (2022-2027)
3.4 Hospital
3.5 Clinic
3.6 Others
4 Follicular Lymphoma Treatment Competition Analysis by Players
4.1 Global Follicular Lymphoma Treatment Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Follicular Lymphoma Treatment as of 2020)
4.3 Date of Key Players Enter into Follicular Lymphoma Treatment Market
4.4 Global Top Players Follicular Lymphoma Treatment Headquarters and Area Served
4.5 Key Players Follicular Lymphoma Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Follicular Lymphoma Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Boehringer Ingelheim GmbH
5.1.1 Boehringer Ingelheim GmbH Profile
5.1.2 Boehringer Ingelheim GmbH Main Business
5.1.3 Boehringer Ingelheim GmbH Follicular Lymphoma Treatment Products, Services and Solutions
5.1.4 Boehringer Ingelheim GmbH Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.1.5 Boehringer Ingelheim GmbH Recent Developments
5.2 Bristol-Myers Squibb Company
5.2.1 Bristol-Myers Squibb Company Profile
5.2.2 Bristol-Myers Squibb Company Main Business
5.2.3 Bristol-Myers Squibb Company Follicular Lymphoma Treatment Products, Services and Solutions
5.2.4 Bristol-Myers Squibb Company Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.2.5 Bristol-Myers Squibb Company Recent Developments
5.3 Celgene Corporation
5.3.1 Celgene Corporation Profile
5.3.2 Celgene Corporation Main Business
5.3.3 Celgene Corporation Follicular Lymphoma Treatment Products, Services and Solutions
5.3.4 Celgene Corporation Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.3.5 Celldex Therapeutics Inc. Recent Developments
5.4 Celldex Therapeutics Inc.
5.4.1 Celldex Therapeutics Inc. Profile
5.4.2 Celldex Therapeutics Inc. Main Business
5.4.3 Celldex Therapeutics Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.4.4 Celldex Therapeutics Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.4.5 Celldex Therapeutics Inc. Recent Developments
5.5 Celltrion Inc.
5.5.1 Celltrion Inc. Profile
5.5.2 Celltrion Inc. Main Business
5.5.3 Celltrion Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.5.4 Celltrion Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.5.5 Celltrion Inc. Recent Developments
5.6 Cellular Biomedicine Group Inc.
5.6.1 Cellular Biomedicine Group Inc. Profile
5.6.2 Cellular Biomedicine Group Inc. Main Business
5.6.3 Cellular Biomedicine Group Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.6.4 Cellular Biomedicine Group Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.6.5 Cellular Biomedicine Group Inc. Recent Developments
5.7 Coherus BioSciences Inc.
5.7.1 Coherus BioSciences Inc. Profile
5.7.2 Coherus BioSciences Inc. Main Business
5.7.3 Coherus BioSciences Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.7.4 Coherus BioSciences Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.7.5 Coherus BioSciences Inc. Recent Developments
5.8 CTI BioPharma Corp.
5.8.1 CTI BioPharma Corp. Profile
5.8.2 CTI BioPharma Corp. Main Business
5.8.3 CTI BioPharma Corp. Follicular Lymphoma Treatment Products, Services and Solutions
5.8.4 CTI BioPharma Corp. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.8.5 CTI BioPharma Corp. Recent Developments
5.9 Curis Inc.
5.9.1 Curis Inc. Profile
5.9.2 Curis Inc. Main Business
5.9.3 Curis Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.9.4 Curis Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.9.5 Curis Inc. Recent Developments
5.10 Dynavax Technologies Corporation
5.10.1 Dynavax Technologies Corporation Profile
5.10.2 Dynavax Technologies Corporation Main Business
5.10.3 Dynavax Technologies Corporation Follicular Lymphoma Treatment Products, Services and Solutions
5.10.4 Dynavax Technologies Corporation Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.10.5 Dynavax Technologies Corporation Recent Developments
5.11 Eisai
5.11.1 Eisai Profile
5.11.2 Eisai Main Business
5.11.3 Eisai Follicular Lymphoma Treatment Products, Services and Solutions
5.11.4 Eisai Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.11.5 Eisai Recent Developments
5.12 EpiZyme Inc.
5.12.1 EpiZyme Inc. Profile
5.12.2 EpiZyme Inc. Main Business
5.12.3 EpiZyme Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.12.4 EpiZyme Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.12.5 EpiZyme Inc. Recent Developments
5.13 F. Hoffmann-La Roche Ltd.
5.13.1 F. Hoffmann-La Roche Ltd. Profile
5.13.2 F. Hoffmann-La Roche Ltd. Main Business
5.13.3 F. Hoffmann-La Roche Ltd. Follicular Lymphoma Treatment Products, Services and Solutions
5.13.4 F. Hoffmann-La Roche Ltd. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.13.5 F. Hoffmann-La Roche Ltd. Recent Developments
5.14 Genentech Inc.
5.14.1 Genentech Inc. Profile
5.14.2 Genentech Inc. Main Business
5.14.3 Genentech Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.14.4 Genentech Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.14.5 Genentech Inc. Recent Developments
5.15 Gilead Sciences Inc.
5.15.1 Gilead Sciences Inc. Profile
5.15.2 Gilead Sciences Inc. Main Business
5.15.3 Gilead Sciences Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.15.4 Gilead Sciences Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.15.5 Gilead Sciences Inc. Recent Developments
5.16 GlaxoSmithKline Plc
5.16.1 GlaxoSmithKline Plc Profile
5.16.2 GlaxoSmithKline Plc Main Business
5.16.3 GlaxoSmithKline Plc Follicular Lymphoma Treatment Products, Services and Solutions
5.16.4 GlaxoSmithKline Plc Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.16.5 GlaxoSmithKline Plc Recent Developments
5.17 Hutchison MediPharma Limited
5.17.1 Hutchison MediPharma Limited Profile
5.17.2 Hutchison MediPharma Limited Main Business
5.17.3 Hutchison MediPharma Limited Follicular Lymphoma Treatment Products, Services and Solutions
5.17.4 Hutchison MediPharma Limited Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.17.5 Hutchison MediPharma Limited Recent Developments
5.18 Immune Design Corp.
5.18.1 Immune Design Corp. Profile
5.18.2 Immune Design Corp. Main Business
5.18.3 Immune Design Corp. Follicular Lymphoma Treatment Products, Services and Solutions
5.18.4 Immune Design Corp. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.18.5 Immune Design Corp. Recent Developments
5.19 ImmunoGen Inc.
5.19.1 ImmunoGen Inc. Profile
5.19.2 ImmunoGen Inc. Main Business
5.19.3 ImmunoGen Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.19.4 ImmunoGen Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.19.5 ImmunoGen Inc. Recent Developments
6 North America
6.1 North America Follicular Lymphoma Treatment Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Follicular Lymphoma Treatment Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Follicular Lymphoma Treatment Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Follicular Lymphoma Treatment Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Follicular Lymphoma Treatment Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Follicular Lymphoma Treatment Market Dynamics
11.1 Follicular Lymphoma Treatment Industry Trends
11.2 Follicular Lymphoma Treatment Market Drivers
11.3 Follicular Lymphoma Treatment Market Challenges
11.4 Follicular Lymphoma Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
1.1 Follicular Lymphoma Treatment Market Overview
1.1.1 Follicular Lymphoma Treatment Product Scope
1.1.2 Follicular Lymphoma Treatment Market Status and Outlook
1.2 Global Follicular Lymphoma Treatment Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Follicular Lymphoma Treatment Market Size by Region (2016-2027)
1.4 Global Follicular Lymphoma Treatment Historic Market Size by Region (2016-2021)
1.5 Global Follicular Lymphoma Treatment Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Follicular Lymphoma Treatment Market Size (2016-2027)
1.6.1 North America Follicular Lymphoma Treatment Market Size (2016-2027)
1.6.2 Europe Follicular Lymphoma Treatment Market Size (2016-2027)
1.6.3 Asia-Pacific Follicular Lymphoma Treatment Market Size (2016-2027)
1.6.4 Latin America Follicular Lymphoma Treatment Market Size (2016-2027)
1.6.5 Middle East & Africa Follicular Lymphoma Treatment Market Size (2016-2027)
2 Follicular Lymphoma Treatment Market Overview by Type
2.1 Global Follicular Lymphoma Treatment Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Follicular Lymphoma Treatment Historic Market Size by Type (2016-2021)
2.3 Global Follicular Lymphoma Treatment Forecasted Market Size by Type (2022-2027)
2.4 Chemotherapy
2.5 Radiotherapy
2.6 Monoclonal Antibodies
2.7 Stem Cell Transplantation
3 Follicular Lymphoma Treatment Market Overview by Application
3.1 Global Follicular Lymphoma Treatment Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Follicular Lymphoma Treatment Historic Market Size by Application (2016-2021)
3.3 Global Follicular Lymphoma Treatment Forecasted Market Size by Application (2022-2027)
3.4 Hospital
3.5 Clinic
3.6 Others
4 Follicular Lymphoma Treatment Competition Analysis by Players
4.1 Global Follicular Lymphoma Treatment Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Follicular Lymphoma Treatment as of 2020)
4.3 Date of Key Players Enter into Follicular Lymphoma Treatment Market
4.4 Global Top Players Follicular Lymphoma Treatment Headquarters and Area Served
4.5 Key Players Follicular Lymphoma Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Follicular Lymphoma Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Boehringer Ingelheim GmbH
5.1.1 Boehringer Ingelheim GmbH Profile
5.1.2 Boehringer Ingelheim GmbH Main Business
5.1.3 Boehringer Ingelheim GmbH Follicular Lymphoma Treatment Products, Services and Solutions
5.1.4 Boehringer Ingelheim GmbH Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.1.5 Boehringer Ingelheim GmbH Recent Developments
5.2 Bristol-Myers Squibb Company
5.2.1 Bristol-Myers Squibb Company Profile
5.2.2 Bristol-Myers Squibb Company Main Business
5.2.3 Bristol-Myers Squibb Company Follicular Lymphoma Treatment Products, Services and Solutions
5.2.4 Bristol-Myers Squibb Company Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.2.5 Bristol-Myers Squibb Company Recent Developments
5.3 Celgene Corporation
5.3.1 Celgene Corporation Profile
5.3.2 Celgene Corporation Main Business
5.3.3 Celgene Corporation Follicular Lymphoma Treatment Products, Services and Solutions
5.3.4 Celgene Corporation Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.3.5 Celldex Therapeutics Inc. Recent Developments
5.4 Celldex Therapeutics Inc.
5.4.1 Celldex Therapeutics Inc. Profile
5.4.2 Celldex Therapeutics Inc. Main Business
5.4.3 Celldex Therapeutics Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.4.4 Celldex Therapeutics Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.4.5 Celldex Therapeutics Inc. Recent Developments
5.5 Celltrion Inc.
5.5.1 Celltrion Inc. Profile
5.5.2 Celltrion Inc. Main Business
5.5.3 Celltrion Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.5.4 Celltrion Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.5.5 Celltrion Inc. Recent Developments
5.6 Cellular Biomedicine Group Inc.
5.6.1 Cellular Biomedicine Group Inc. Profile
5.6.2 Cellular Biomedicine Group Inc. Main Business
5.6.3 Cellular Biomedicine Group Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.6.4 Cellular Biomedicine Group Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.6.5 Cellular Biomedicine Group Inc. Recent Developments
5.7 Coherus BioSciences Inc.
5.7.1 Coherus BioSciences Inc. Profile
5.7.2 Coherus BioSciences Inc. Main Business
5.7.3 Coherus BioSciences Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.7.4 Coherus BioSciences Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.7.5 Coherus BioSciences Inc. Recent Developments
5.8 CTI BioPharma Corp.
5.8.1 CTI BioPharma Corp. Profile
5.8.2 CTI BioPharma Corp. Main Business
5.8.3 CTI BioPharma Corp. Follicular Lymphoma Treatment Products, Services and Solutions
5.8.4 CTI BioPharma Corp. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.8.5 CTI BioPharma Corp. Recent Developments
5.9 Curis Inc.
5.9.1 Curis Inc. Profile
5.9.2 Curis Inc. Main Business
5.9.3 Curis Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.9.4 Curis Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.9.5 Curis Inc. Recent Developments
5.10 Dynavax Technologies Corporation
5.10.1 Dynavax Technologies Corporation Profile
5.10.2 Dynavax Technologies Corporation Main Business
5.10.3 Dynavax Technologies Corporation Follicular Lymphoma Treatment Products, Services and Solutions
5.10.4 Dynavax Technologies Corporation Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.10.5 Dynavax Technologies Corporation Recent Developments
5.11 Eisai
5.11.1 Eisai Profile
5.11.2 Eisai Main Business
5.11.3 Eisai Follicular Lymphoma Treatment Products, Services and Solutions
5.11.4 Eisai Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.11.5 Eisai Recent Developments
5.12 EpiZyme Inc.
5.12.1 EpiZyme Inc. Profile
5.12.2 EpiZyme Inc. Main Business
5.12.3 EpiZyme Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.12.4 EpiZyme Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.12.5 EpiZyme Inc. Recent Developments
5.13 F. Hoffmann-La Roche Ltd.
5.13.1 F. Hoffmann-La Roche Ltd. Profile
5.13.2 F. Hoffmann-La Roche Ltd. Main Business
5.13.3 F. Hoffmann-La Roche Ltd. Follicular Lymphoma Treatment Products, Services and Solutions
5.13.4 F. Hoffmann-La Roche Ltd. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.13.5 F. Hoffmann-La Roche Ltd. Recent Developments
5.14 Genentech Inc.
5.14.1 Genentech Inc. Profile
5.14.2 Genentech Inc. Main Business
5.14.3 Genentech Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.14.4 Genentech Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.14.5 Genentech Inc. Recent Developments
5.15 Gilead Sciences Inc.
5.15.1 Gilead Sciences Inc. Profile
5.15.2 Gilead Sciences Inc. Main Business
5.15.3 Gilead Sciences Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.15.4 Gilead Sciences Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.15.5 Gilead Sciences Inc. Recent Developments
5.16 GlaxoSmithKline Plc
5.16.1 GlaxoSmithKline Plc Profile
5.16.2 GlaxoSmithKline Plc Main Business
5.16.3 GlaxoSmithKline Plc Follicular Lymphoma Treatment Products, Services and Solutions
5.16.4 GlaxoSmithKline Plc Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.16.5 GlaxoSmithKline Plc Recent Developments
5.17 Hutchison MediPharma Limited
5.17.1 Hutchison MediPharma Limited Profile
5.17.2 Hutchison MediPharma Limited Main Business
5.17.3 Hutchison MediPharma Limited Follicular Lymphoma Treatment Products, Services and Solutions
5.17.4 Hutchison MediPharma Limited Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.17.5 Hutchison MediPharma Limited Recent Developments
5.18 Immune Design Corp.
5.18.1 Immune Design Corp. Profile
5.18.2 Immune Design Corp. Main Business
5.18.3 Immune Design Corp. Follicular Lymphoma Treatment Products, Services and Solutions
5.18.4 Immune Design Corp. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.18.5 Immune Design Corp. Recent Developments
5.19 ImmunoGen Inc.
5.19.1 ImmunoGen Inc. Profile
5.19.2 ImmunoGen Inc. Main Business
5.19.3 ImmunoGen Inc. Follicular Lymphoma Treatment Products, Services and Solutions
5.19.4 ImmunoGen Inc. Follicular Lymphoma Treatment Revenue (US$ Million) & (2016-2021)
5.19.5 ImmunoGen Inc. Recent Developments
6 North America
6.1 North America Follicular Lymphoma Treatment Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Follicular Lymphoma Treatment Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Follicular Lymphoma Treatment Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Follicular Lymphoma Treatment Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Follicular Lymphoma Treatment Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Follicular Lymphoma Treatment Market Dynamics
11.1 Follicular Lymphoma Treatment Industry Trends
11.2 Follicular Lymphoma Treatment Market Drivers
11.3 Follicular Lymphoma Treatment Market Challenges
11.4 Follicular Lymphoma Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
